Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Watchlisten für Ihre Werte
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über 4D MOLECULAR THERAPEUTICS, INC.
23.11.4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 C..
10.11.4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
10.11.4D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condi..
10.11.4D Molecular Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine..
10.11.Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Reports Q3 Revenue $1.4M
10.11.4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
29.10.4D Molecular Therapeutics Prices Stock Offering at $25 Per Share; Shares Decline
29.10.4D Molecular Therapeutics Prices Stock Offering at $25 Per Share
29.10.4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
27.10.4D Molecular Therapeutics Commences Public Offering of 4.5 Million Common Shares
26.10.4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
26.10.4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
26.10.4D MOLECULAR THERAPEUTICS INC. : Other Events (form 8-K)
26.10.4D MOLECULAR THERAPEUTICS : 4D-310 & 4D-110 Clinical Data Conference Call Presentation
25.10.4D MOLECULAR THERAPEUTICS : Reports Interim Results from the 4D-310 Phase 1/2 Clinical Tri..
25.10.4D Molecular Therapeutics, Inc. Reports Interim Results from the 4D-310 Phase 1/2 Clini..
25.10.INSIDER SELL : 4d Molecular Therapeutics
13.10.4D MOLECULAR THERAPEUTICS INC. : Other Events (form 8-K)
11.10.4D MOLECULAR THERAPEUTICS' : 4D-125 Drug Shows Potential in Eye Disease Trial
10.10.4D MOLECULAR THERAPEUTICS : ASRS 2021 Annual Meeting – 4D-125 for XLRP Phase 1/2 Cli..
10.10.4D MOLECULAR THERAPEUTICS : Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Cli..
10.10.4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Cl..
06.10.Health Care Stocks Trade Lower Premarket Wednesday
06.10.4D MOLECULAR THERAPEUTICS : Obtains FDA Clearance for Phase 1/2 Trial of Wet Age-Related M..
06.10.4D MOLECULAR THERAPEUTICS : Announces FDA Clearance of IND Application for 4D-710, an A101..
06.10.4D MOLECULAR THERAPEUTICS : Announces FDA Clearance of IND Application for 4D-150, a Dual-..
06.10.4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual..
06.10.4D Molecular Therapeutics Gets FDA Clearance for Two IND Applications
06.10.4D Molecular Therapeutics, Inc. announced that it has received $4 million in funding fr..
04.10.CHOROIDEREMIA PIPELINE : Industry Analysis, Drugs, Pipeline, Treatment and Key Companies b..
01.10.INSIDER SELL : 4d Molecular Therapeutics
29.09.INSIDER SELL : 4d Molecular Therapeutics
29.09.4D MOLECULAR THERAPEUTICS : to Participate in Chardan's 5th Annual Genetic Medicines Confe..
24.09.4D MOLECULAR THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Stat..
24.09.4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data ..
12.08.4D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
12.08.4D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
12.08.4D MOLECULAR THERAPEUTICS : Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Reports Q2 Rev..
12.08.4D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
12.08.4D Molecular Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Qua..
12.08.4D Molecular Therapeutics, Inc. Appoints Nadine Greiner as Chief Human Resources Office..
25.06.4D MOLECULAR THERAPEUTICS INC. : Termination of a Material Definitive Agreement, Other Eve..
25.06.4D Molecular Therapeutics, Inc. Announces Rare Disease Ophthalmology Product Candidate ..
25.06.4D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Microcap Value Index
25.06.4D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Growth Index
25.06.4D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Microcap Growth Index
25.06.4D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Value Index
25.06.4D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell 3000E Index
25.06.4D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to Russell Microcap Index
25.06.4D-110 : Initial clinical safety data at both of the two dose levels in the Phase 1 clinic..
24.06.4D Molecular Says Roche Stops Trial, Cancels Licensing Deal for Eye Drug; Shares Sink
24.06.4D Molecular Shares Hit 52-Week Low After Roche Ends Collaboration Agreement
24.06.4D Molecular Therapeutics Gets Termination Notice From Roche
24.06.4D MOLECULAR THERAPEUTICS : Announces Rare Disease Ophthalmology Product Candidate Portfol..
21.06.4D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) added to S&P Global BMI Index
09.06.Certain Warrants of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement ..
09.06.Certain Stock Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agree..
09.06.16,833,726 Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agr..
08.06.CHOROIDEREMIA PIPELINE : Emerging Therapies and Key pharma players involved by DelveInsigh..
07.06.4D MOLECULAR THERAPEUTICS : Appoints Carolyne Zimmermann as Chief Business Officer
07.06.4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer
03.06.4D MOLECULAR THERAPEUTICS : to Participate in Goldman Sachs 42nd Annual Global Healthcare ..
20.05.4D MOLECULAR THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form..
13.05.4D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
13.05.4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and P..
13.05.4D Molecular Therapeutics, Inc. Announces Unaudited Earnings Results for the First Quar..
12.05.4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4..
12.05.4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4..
04.05.4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technolog..
30.04.4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Co..
27.04.4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Ann..
27.04.4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Ann..
06.04.Mr. William Burkoth to Not Stand for Re-Election as Director of 4D Molecular Therapeuti..
31.03.JOHN MARTIN : John Martin, Who Built Gilead Into HIV, Hepatitis Powerhouse, Dies
26.03.4D MOLECULAR THERAPEUTICS : Posts Narrower Net Loss, Higher Revenue in 2020
1  2Weiter